Teva Pharmaceutical Industries Limited Q3 2026 Earnings Recap

Teva shares rose 3.0% after earnings, with investors responding to growth in the innovative portfolio and higher margins despite a 2% decline in revenue. Generics weakness—largely tied to lower generic REVLIMID contribution—remains a counterweight.

Key Takeaways

• Revenue was $4.4 billion, down 2% year over year; gross margin increased 345 basis points to 58.7%.
• EBITDA grew 7% and non-GAAP EPS rose 10%.
• Innovative portfolio revenue increased 32%; AUSTEDO sales were $751 million (+21%), UZEDY $85 million (+96%), and AJOVY $269 million (+61%).
• Generics revenue declined 16%, largely due to a lower contribution from generic REVLIMID.
• Teva said it discontinued the phase II emrusolmin study after an interim futility analysis; management reported no safety concerns.